{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.0","upperLimit":"80.8","value":"69.8"},{"groupId":"OG001","lowerLimit":"62.7","upperLimit":"83.0","value":"73.8"},{"groupId":"OG002","lowerLimit":"60.0","upperLimit":"78.8","value":"70.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"100"}],"units":"Participants"}],"description":"ORR is the percent of participants achieving either a complete remission (CR) or partial remission (PR) according to the 2007 IWG criteria. Analyses of efficacy endpoints were performed separately for each cohort, according to IWG 2007. For cohort A and B, if the bone marrow was involved by lymphoma before treatment, the infiltrate must have cleared on repeat bone marrow biopsy. For cohort C, no evidence of FDG-avid disease in bone marrow was required in all participants in lieu of bone marrow aspirate/ biopsy.\n\nCR is the percent of participants with a best overall response (BOR) of CR (disappearance of all evidence of disease) according to the 2007 IWG criteria, based on IRRC assessment.\n\nPR is the percent of participants with a best overall response (BOR) of PR (regression of measurable disease and no new sites) according to the 2007 IWG criteria, based on IRRC assessment.\n\nConfidence interval based on Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"OG000","title":"Cohort A: Post-Transplant, Never Taken Brentuximab Vedotin"},{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"OG001","title":"Cohort B: Post Transplant, Brentuximab Vedotin Taken Post-Autologous Stem Cell Transplant"},{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"OG002","title":"Cohort C: Post Transplant, Brentuximab Vedotin Taken Pre-and/or Post-Autologous Stem Cell Transplant"}],"paramType":"NUMBER","populationDescription":"All treated Cohort A, B and C participants","reportingStatus":"POSTED","timeFrame":"From first dose to the date of initial objectively documented progression or the date of subsequent therapy, or death whichever occurred first (up to approximately 100 months)","title":"Objective Response Rates (ORR) Based on Investigator Assessments for Cohorts A, B, and C","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}